President & Chief Executive Officer
An accomplished CPA, Amy co-founded Bio-Tissue® in 1997 and TissueTech in 2001 with the vision of commercializing cryopreserved amniotic membrane as a platform technology for the treatment of ocular surface diseases. Since its inception, Amy has presided over this mission, building Bio-Tissue into the industry leader in this sector. Through excellent financial and corporate management, she has guided the company through impressive levels of annual growth and continues to lead and drive the expansion of the technology’s applications into other healthcare sectors. Prior to founding Bio-Tissue, Amy spent 10 years with the big five accounting firms, Ernst & Young and Price Waterhouse. Amy Tseng graduated from the National Taiwan University and received her MBA from the University of Southern California.
Chief Scientific Officer
Dr. Scheffer C. G. Tseng co-founded TissueTech™ and Bio-Tissue®. Dr. Tseng is a world-renowned surgeon in ocular surface reconstruction and a widely-published physician scientist with more than 300 peer-reviewed clinical and scientific papers. He pioneered limbal stem cell transplantation and developed and commercialized the CryoTek® process to preserve the natural wound healing properties of amniotic membrane for ocular surface reconstruction and wound healing. His research focus for the past 30 years has been to identify the active biological components of human placental tissues, to develop alternative products to deliver the efficacy of their natural healing properties, and to expand the benefits of its clinical applications.
Dr. Scheffer C. G. Tseng received his MD at National Taiwan University and his PhD in Experimental Pathology at the University of California, San Francisco. He completed his residency for Ophthalmology at the Wilmer Eye Institute at Johns Hopkins and his fellowship in Cornea and External Diseases at Massachusetts Eye and Ear Infirmary. Before he co-founded the Company, he was a Chair Professor at Bascom Palmer Eye Institute, University of Miami School of Medicine.
Chief Financial Officer
Michael Cornelius joined TissueTech in 2014 as an accomplished financial executive with more than 25 years of experience in public accounting and with public and private corporations. Most recently, he was the CFO and co-founder of a start-up medical device company, Emunamedica LLC. Prior to that, Mike was the CFO of Stiefel Laboratories, the largest privately-held dermatology company in the world, before it was acquired by GlaxoSmithKlein in 2009. Mike joined Stiefel in 1999 and rose to lead its global financial operations in 2005. He was an integral member of the executive leadership team providing global strategic and operational direction. Michael Cornelius received his Bachelor of Science Degree in Business Administration from Indiana University of Pennsylvania and he is a Certified Public Accountant. Mike started his career with the international accounting and consulting firm, Grant Thornton, where he specialized in US and International tax planning and also held senior level finance positions with IVAX Corporation and Sunglass Hut International.
Chief Commercial Officer
Tom Daniells joined TissueTech in 2012 with more than 25 years of sales, marketing, international and business development experience in ophthalmology. He started his career at Alcon Surgical, where his career progressed rapidly to the role of Director of Marketing. In 2004, Tom joined Optos, a high-growth company, as the Director of Sales and then transitioned into the Vice President of Marketing role. With Tom’s strategic direction, the company grew from less than $10 million to more than $140 million in revenue. In his last role as Vice President of Business Development at Optos, Tom led the acquisition of two companies, including Opko Health, Inc. Tom Daniells received his Bachelor of Science in Business Administration and Marketing from California State University in Fresno and an MBA with an emphasis in international marketing from the University of California, Irvine.
Vice President, Operations
Alan Petro joined the executive team in 2015 to lead TissueTech’s procurement, supply chain, manufacturing, distribution and facilities operations. He has 30 years of experience leading product development, manufacturing, quality management and regulatory affairs for medical device, pharmaceutical and biotechnology companies. During this time, he has held executive level positions with several market- leading companies including Siemens Healthcare, Carl Zeiss, Meditec and Acuson, as well as successfully positioning several start-up companies for acquisition. Alan holds a Bachelor of Science in Materials and Metallurgical Engineering from the University of Michigan, an MBA from Marylhurst University, and a MJ in Healthcare Law from Loyola University of Chicago.
Chief Executive Officer
Amniox® Medical, Inc.
After joining the Amniox® Medical Board of Directors in 2014, Tom Dugan became the Company’s Chief Executive Officer in 2015. Prior to Amniox, Tom was President and a member of the board of directors of SurgiQuest, Inc. From 2008 until 2013, he served as President, North America, Smith & Nephew Wound Management and served on the Global Executive Management team of Smith & Nephew’s $1.3 billion wound management business. At Smith & Nephew, he led the turnaround of the North American business, driving growth at over twice the market rate, and established them as a leading player in the Negative Pressure Wound Therapy market. Previously, Tom served as the Senior Vice President of Sales & Marketing for SonoSite, Inc. world leader in hand carried ultrasound. He also served as President of InterVascular, Inc. and Corporate Vice President of Business Development of Datascope. He was the Vice President of Marketing and ran business development for U.S. Surgical/Tyco Healthcare (now Covidien) during a period of significant M&A activity. He also served on the Board of Directors of RITA Medical Systems, Inc. and two other venture backed medical device companies.
Bennett Ortiz joined TissueTech, Inc., in 2015 and has more than 20 years of experience in sales and operations. He leads the company's Commercial Operations organization to support both the Bio-Tissue and Amniox business units. Under his leadership, the Commercial Operations team has experienced significant transformation and growth. His primary responsibilities are to oversee the Sales Operations, Sales Logistics, Customer Service and Sales Support functions; while continuing to implement revenue-generating technologies.
Prior to joining the company, Ben was Senior Commercial Excellence Quality Leader for Microsoft. He has held positions of increasing responsibility for other companies, including Univar, Zimmer, Inc., Cordis, Johnson & Johnson and GE (General Electric). He is a graduate of the State University of New York, where he obtained a Master of Science in Mechanical Engineering.
Corporate Legal Counsel
and Chief Compliance Officer
Devin Buckley joined TissueTech in 2013 with more than 12 years of experience in the life science industry. Devin was the Senior Vice President and General Counsel at Stiefel Laboratories, where he helped to build what became the world’s largest dermatology business. Devin previously held executive positions with United Technologies, UTC/Pratt & Whitney, Day, Berry & Howard and Our Kids of Miami-Dade. Devin received his bachelor’s degree from Yale and his JD from Georgetown.